Clinical Trials
2 trialsNCT05142241 2025-11-18
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02150213 2016-12-05
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Novartis
Phase 2 Completed